We Claim,

1. A fully liquid multi-dose immunogenic composition, wherein 0.5 ml of the composition comprises~~ing~~:
   i) a diphtheria toxoid, (D) in an amount of 10 Lf to 25 Lf, adsorbed onto aluminium salt adjuvant having percentage adsorption of at least 50%;
   ii) a tetanus toxoid, (T)in an amount of 2 Lf to 10 Lf, adsorbed onto aluminium salt adjuvant having percentage adsorption of at least 40%;
   iii) an inactivated whole cell pertussis, (wP) containing inactivated Bordetella pertussis strains 134, 509, 25525 and 6229 in a ratio of 1:1:0.25:0.25, in an amount of 12 IOU to 16 IOU~~or acellular pertussis, (aP)~~;
   iv) a hepatitis B virus surface antigen, (HBsAg) in the an amount of 7 µg to 15 µg, adsorbed onto aluminium salt adjuvant having percentage adsorption of at least 50%;
   v) a Haemophilus influenzae type b antigen, (Hib) in an amount of 7 µg to 13 µg;
   vi) an inactivated polio virus antigen, (IPV) ~~wherein~~ containing IPV Type 1 in an amount of 1 - ~~50~~ 25DU, IPV Type 2 in an amount of 1 – 10 DU ~~per 0.5 ml~~ and IPV Type 3 in an amount of 1 - ~~50~~ 20DU ~~per 0.5 ml~~; and
   vii) total aluminium content (Al3+) in the range of 0.1 mg to 0.6 mg; and
   ~~vii)~~viii) ~~a combination of~~ preservative comprising 2-phenoxyethanol in an amount of 1 - 6 mg (v/v); methylparaben in an amount of0.1 – 1.5 mg (w/v) and propylparaben in an amount of 0.05 – 0.2 mg (w/v);or
   2-phenoxyethanol in an amount of 1 - 6 mg (v/v) and methylparaben in an amount of 0.1 – 1.5 mg (w/v); or
   2-phenoxyethanol in an amount of 1 - 6 mg (v/v) and propylparaben in an amount of 0.05 – 0.2 mg (w/v)~~and at least one other preservative~~.

~~2. The immunogenic composition as claimed in claim 1, wherein the inactivated whole cell pertussis in the composition is of Bordetella pertussis strains 134, 509, 25525 and 6229 in a ratio of 1 :1 :0.25:0.25.~~

~~3. The immunogenic composition as claimed in claim 1, wherein the acellular pertussis antigen comprises one or more antigens selected from modified adenylate cyclase, Pertussis toxoid (PT), Filamentous hemagglutinin (FHA), Pertactin (P69 or PRN) or Fimbrial proteins (FIM 1 , 2 and 3).~~

~~4.~~2. The immunogenic composition as claimed in claim 1, wherein the Hib antigen is a Hib polyribosylribitol phosphate (PRP) polysaccharide conjugated to a carrier protein using a cyanylation conjugation chemistry or reductive animation conjugation chemistry, wherein said cyanylation reagent is selected from Cyanogen Bromide, l-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP)l -cyano-4-pyrrolidinopyridinium tetrafluorborate (CPPT), 1-cyanoimidazole namely (1 -Cl), 1 -cyanobenzotriazole(1-CBT) or 2-cyanopyridazine-3(2H)one (2-CPO); and carrier protein is selected from a group comprising of tetanus toxoid, CRM_{197}, Diphtheria toxoid, Neisseria meningitidis outer membrane complex, fragment C of tetanus toxoid, pertussis toxoid, protein D of H. influenzae, E.coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa, outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), pneumococcal PhtD, pneumococcal surface proteins BVH-3 and BVH-1 1 , protective antigen (PA) of Bacillus anthracis and detoxified edema factor (EF) and lethal factor (LF) of Bacillus anthracis, ovalbumin, keyhole limpet hemocyanin (KLH), human serum albumin, bovine serum albumin (BSA), purified protein derivative of tuberculin (PPD), synthetic peptides, heat shock proteins pertussis proteins, cytokines, lymphokines, hormones, growth factors, artificial proteins comprising multiple human CD4+ T cell epitopes from various pathogen- derived antigens such as N 19, iron-uptake proteins, toxin A or B from C. difficile and S.agalactiae proteins with or without linker.

~~5. The immunogenic composition as claimed in claim 1 , wherein the composition additionally comprises IPV Type 2 in an amount of 1 - 20 DU per 0.5 ml~~

~~6.~~3. The immunogenic composition as claimed in claim 1~~ and 5~~, wherein the IPV antigens are Salk strains selected from the group of~~Type 1 the~~ Mahoney, MEF-1, Saukett,

~~strain~~ or Sabin strain~~s ; and/or wherein the~~selected from the group of Sabin ~~IPV~~ Type 1, Sabin Type 2 ~~is the MEF-1 strain or Sabin strain; and/or wherein the IPV~~and Sabin Type 3 ~~is the Saukett strain or Sabin strain~~.

~~7. The immunogenic composition as claimed in claim 1 , wherein the said other preservative is selected from the group of Benzethonium chloride (Phemerol), Phenol, m-cresol, Formaldehyde, benzalkonium chloride, benzyl alcohol, chlorobutanol, p-chlor-m-cresol, benzyl alcohol and paraben ester selected from the group of methylparaben, ethylparaben, propylparaben and butylparaben.~~

~~8. The immunogenic composition as claimed in claim 1, wherein the composition comprises 2-phenoxyethanol in an amount of 1 - 6 mg per 0.5 ml (v/v); methylparaben in an amount of 0.1 - 1.5 mg per 0.5 ml (w/v) and propylparaben in an amount of 0.05 - 0.2 mg per 0.5 ml (w/v).~~

~~9. The immunogenic composition as claimed in claim 1 , wherein the D, T, wP, HBsAg, Hib and IPV are not adsorbed onto an adjuvant.~~

~~10.~~4. The immunogenic composition as claimed in claim 1, wherein the D, T and HBsAg are individually adsorbed onto an aluminium salt (Al 3+) adjuvant selected from ~~the group of aluminium salt ($A1^{3+}$) such as~~ aluminium hydroxide ($Al(OH)_3$) ~~or~~ and aluminium phosphate (~~$A1P0_4$~~$A1PO_4$)~~, alum, calcium phosphate, MPLA, 3D-MPL, QS21 , a CpG-containing oligodeoxynucleotide adjuvant, liposome or oil-in-water emulsion~~.

~~11. The immunogenic composition as claimed in claim 10, wherein the D, T, HBsAg are individually adsorbed onto aluminium phosphate ($A1P0_4$) adjuvant.~~

~~12. The immunogenic composition as claimed in claim 10, wherein the D antigen are adsorbed onto aluminium salt having percentage adsorption of at least 50%.~~

~~13. The immunogenic composition as claimed in claim 10, wherein the T antigen are adsorbed onto aluminium salt having percentage adsorption of at least 40%.~~

~~14. The immunogenic composition as claimed in claim 10, wherein the HBsAg antigen are adsorbed onto aluminium salt having percentage adsorption of at least 50%.~~

~~15.~~5. The immunogenic composition as claimed in claim~~s~~ 1 ,~~ 5 and 6,~~ wherein the IPV antigens are adsorbed onto aluminium salt of ~~hydroxide ($Al(OH)_3$) or~~ phosphate ($A1P0_4$) ~~having~~ and percentage adsorption of IPV Type 1 is in range of 10 - 100 %, IPV Type 2 is in range of 60 - 100% and IPV Type 3 is in range of 10 - 100 %.

~~16.~~6. The immunogenic composition as claimed in claim 1, wherein the percentage of adsorption of Hib antigen on to ~~any~~ the adjuvant is less than 20%.

~~17. The immunogenic composition as claimed in any one of claims 1 to 16, wherein the total aluminium content (Al^{3+}) in the composition is in an amount of 0.1 to 0.6 mg per 0.5 ml.~~

~~18.~~7. The immunogenic composition as claimed in claim 1, wherein the composition further comprises a dilution medium or buffer selected from sodium chloride or phosphate buffer saline.

~~19.~~8. The immunogenic composition as claimed in claim ~~18~~7, wherein the composition comprises sodium chloride as dilution medium or buffer in a concentration of 0.5% to 1.5%.

~~20. The immunogenic composition as claimed in claim 1 , wherein the composition further comprises a pharmaceutically acceptable transporter, excipient, binder, carrier, isotonic agent, emulsifier or humectant.~~

~~21. The immunogenic composition as claimed in claim 20, wherein the composition comprises pharmaceutically acceptable excipient selected from the group of sugars, polyols, surfactants, polymers, salts, aminoacids or pH modifiers.~~

22. The immunogenic composition as claimed in any one of claims 3 to 21 , wherein the single dose immunogenic composition is free of preservative.

23. The immunogenic composition as claimed in claim 1 , wherein the composition further comprises one or more antigen selected from group of Haemophilus influenzae (a, c, d, e, f serotypes and the unencapsulated strains), Hepatitis (A, C, D, E, F and G strains), rotavirus, Neisseria meningitidis A antigen(s), Neisseria meningitidis C antigen(s), Neisseria meningitidis W-135 antigen(s), Neisseria meningitidis Y antigen(s), Neisseria meningitidis X antigen(s), Streptococcus Pneumoniae antigen(s), Neisseria meningitidis B antigen(s), Staphylococcus aureus antigen(s), Anthrax, BCG, Human papilloma virus, Salmonella typhi antigen(s), non-typhoidal Salmonella antigens, modified adenylate cyclase, Malaria Antigen (RTS,S), Measles, Mumps, Rubella, Flavivirus Antigen, Dengue, Zika, Ebola, Chikungunya, Japanese encephalitis, and Diarrheal antigens.

24. The immunogenic composition as claimed in any one of the claims 1 -23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 Lf to 10 Lf; wP antigen in an amount of about 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 - 50 DU, and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 50 DU, respectively; total aluminium content (A1) in an amount of 0.1 to 0.6 mg; 2-Phenoxyethanol in an amount of 1 to 6 mg (v/v); methylparaben in an amount of 0.1 - 1.5 mg (w/v).

25. The immunogenic composition as claimed in any one of the claims 1-23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -50 DU, Type 2(MEF-1 strain or Sabin strain) in an amount of 1 - 20 DU and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 50 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2-

~~Phenoxyethanol in an amount of about 1 to 6 mg (v/v); methylparaben in an amount of 0.1 - 1.5 mg (w/v).~~

~~26. The immunogenic composition as claimed in any one of the claims 1-23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -50 DU, and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 50 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2- Phenoxyethanol in an amount of 1 to 6 mg (v/v); propylparaben in an amount of 0.05 - 0.2 mg (w/v).~~

~~27. The immunogenic composition as claimed in any one of the claims 1 -23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Llib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -50 DU, Type 2(MEF-1 strain or Sabin strain) in an amount of 1 - 20 DU and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 50 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2-Phenoxyethanol in an amount of 1 to 6 mg (v/v); propylparaben in an amount of 0.05 - 0.2 mg (w/v).~~

~~28. The immunogenic composition as claimed in any one of the claims 1-23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -50 DU, and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 50DU, respectively; total aluminium content (A1) in an amount of 0.1 to 0.6 mg; 2- Phenoxyethanol in an amount of 1 to 6 mg (v/v); methylparaben in an amount of 0.1 - 1.5 mg (w/v); propylparaben in an amount of 0.05 - 0.2 mg (w/v).~~

29. The immunogenic composition as claimed in any one of the claims 1-23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 – 50 DU, Type 2(MEF-l strain or Sabin strain) in an amount of 1 – 20 DU and Type 3(Saukett strain or Sabin strain) in an amount of 1 – 50 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2-Phenoxyethanol in an amount of 1 to 6 mg (v/v); methylparaben in an amount of 0.1 – 1.5 mg (w/v); propylparaben in an amount of 0.05 – 0.2 mg (w/v).

30. The immunogenic composition as claimed in any one of the claims 1 -23. wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 Lf to 10 Lf; wP antigen in an amount of about 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, and Type 3(Saukett strain or Sabin strain) in an amount of 1 – 20 DU, respectively; total aluminium content ($A1^{J+}$) in an amount of 0.1 to 0.6 mg;2-Phenoxyethanol in an amount of 1 to 6 mg (v/v); methylparaben in an amount of 0.1 – 1.5 mg (w/v).

31. The immunogenic composition as claimed in any one of the claims 1-23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, Type 2(MEF l strain or Sabin strain) in an amount of 1 – 10 DU and Type 3(Saukett strain or Sabin strain) in an amount of 1 – 20 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2-Phenoxyethanol in an amount of about 1 to 6 mg (v/v); methylparaben in an amount of 0.1 – 1.5 mg (w/v).

32. The immunogenic composition as claimed in any one of the claims 1-23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an

amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 20 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2- Phenoxyethanol in an amount of 1 to 6 mg (v/v); propylparaben in an amount of 0.05 - 0.2 mg (w/v).

33. The immunogenic composition as claimed in any one of the claims 1-23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, Type 2(MEF-1 strain or Sabin strain) in an amount of 1 - 10 DU and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 20 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2-Phenoxyethanol in an amount of 1 to 6 mg (v/v); propylparaben in an amount of 0.05 - 0.2 mg (w/v).

34. The immunogenic composition as claimed in any one of the claims 1 -23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 20 DU, respectively; total aluminium content ($A1^{J+}$) in an amount of 0.1 to 0.6 mg; 2- Phenoxyethanol in an amount of 1 to 6 mg (v/v); methylparaben in an amount of 0.1 - 1.5 mg (w/v); propylparaben in an amount of 0.05 - 0.2 mg (w/v).

35. The immunogenic composition as claimed in any one of the claims 1 -23, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, Type 2(MEF-1 strain or Sabin strain) in an

~~amount of 1 - 10 DU and Type 3(Saukett strain or Sabin strain) in an amount of 1 - 20 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2-Phenoxyethanol in an amount of 1 to 6 mg (v/v); methylparaben in an amount of 0.1 - 1.5 mg (w/v); propylparaben in an amount of 0.05 - 0.2 mg (w/v).~~

~~36. The immunogenic composition as claimed in any one of the preceding claims, wherein 0.5 ml of the composition comprises either one of the following:~~

- ~~D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 pg; Hib antigen in an amount of 8 pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40DU, and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or~~

- ~~D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 pg; Hib antigen in an amount of 10 pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 gg; Hib antigen in an amount of 13 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content ($A1^{3+}$) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v).~~

~~37. The immunogenic composition as claimed in any one of the preceding claims, wherein 0.5 ml of the composition comprises either one of the following:~~

- D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 gg; Hib antigen in an amount of 8 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

- D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 gg; Hib antigen in an amount of 10 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

- D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 gg; Hib antigen in an amount of 13 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v).

38. The immunogenic composition as claimed in any one of the preceding claims, wherein 0.5 ml of the composition comprises either one of the following:

- D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 gg; Hib antigen in an amount of 8 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively;

~~total aluminium content ($A1^{3+}$) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or~~

- ~~D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 pg; Hib antigen in an amount of 10 pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v).~~

- ~~D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 pg; Hib antigen in an amount of 13 pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mgy 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v).~~

~~39. The immunogenic composition as claimed in any one of the preceding claims, wherein 0.5 ml of the composition comprises either one of the following:~~

- ~~D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 pg; Hib antigen in an amount of 8 pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or~~

- ~~D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 pg; Hib antigen in an amount of 10~~

~~pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 gg; Hib antigen in an amount of 13 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v).~~

~~40. The immunogenic composition as claimed in any one of the preceding claims, wherein 0.5 ml of the composition comprises either one of the following:~~

- ~~D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 gg; Hib antigen in an amount of 8 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or~~

- ~~D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 gg; Hib antigen in an amount of 10 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or~~

- D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 gg; Hib antigen in an amount of 13 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total ;aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v).

41. The immunogenic composition as claimed in any one of the preceding claims, wherein 0.5 ml of the composition comprises either one of the following:

- D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 gg; Hib antigen in an amount of 8 gg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

- D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 pg; Hib antigen in an amount of 10 pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

~~D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 pg; Hib antigen in an amount of 13 pg; IPV antigen, type 1 (Mahoney strain or Sabin strain) in an amount of 40 DU, type 2 (MEF-1 strain or Sabin strain) in an amount of 8 DU and type 3 (Saukett strain or Sabin strain) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v).~~

~~42.~~9. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µ~~p~~g; Hib antigen in an amount of 8 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; ~~FIBsAg~~ HBsAg in an amount of 15 µ~~p~~g; Hib antigen in an amount of 10 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µ~~g~~g; Hib antigen in an amount of 13 µ~~g~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU,

respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v).

~~43.~~10. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~,1 wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µgg; Hib antigen in an amount of 8 µgg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 4 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µgg; Hib antigen in an amount of 10 µgg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 4 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µgg; Hib antigen in an amount of 13 µgg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 4 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v).

~~44.~~11. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µ~~p~~g; Hib antigen in an amount of 8 µ~~p~~g; IPV antigen type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{J+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µ~~p~~g; Hib antigen in an amount of 10 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v)~~.~~; or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µ~~p~~g; Hib antigen in an amount of 13 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v).

~~45.~~12. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µ~~p~~g; Hib antigen in an amount of 8

µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20DU, type 2 (MEF-l strain ~~or Sabin strain~~) in an amount of 4 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 10 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, type 2 (MEF-l strain ~~or Sabin strain~~) in an amount of 4 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al 3,+) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 13 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 4 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v).

~~46.~~13. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µpg; Hib antigen in an amount of 8 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an

amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 10 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 13 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 20 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 16 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v).

~~47.~~14. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µpg; Hib antigen in an amount of 8 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of ~~20~~ 7.5DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of ~~4~~ 1.5DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of ~~1~~6 DU, respectively; total aluminium content (AL ^{1}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 10 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of ~~20~~ 7.5DU, type 2 (MEF-l strain ~~or Sabin strain~~) in an amount of ~~4~~ 1.5DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of ~~1~~6 DU, respectively; total aluminium content (Al^{3+} ~~–f~~) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 13 µpg; IPV antigen, type 1 (Mahoney strain µ~~or Sabin strain~~) in an amount of ~~20~~ 7.5DU, type 2 (MEF-l strain ~~or Sabin strain~~) in an amount of ~~4~~ 1.5DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of ~~1~~6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v).

~~48.~~15. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in, an amount of 12 IOU; HBsAg in an amount of 8 µpg; Hib antigen in an amount of 8 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, and type 3 (Saukett strain ~~or Sabinstrain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of

10 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{J+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 13 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v).

~~49.~~16. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µpg; Hib antigen in an amount of 8 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 10 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, type 2 (MEF-l strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total

aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 13 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v).

~~50.~~17. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1 wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µpg; Hib antigen in an amount of 8 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 10 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);propylparaben in an amount of 0.1 mg (w/v).

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 13 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v).

~~51.~~18. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µpg; Hib antigen in an amount of 8 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 10 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU. type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content ($Al^{3\ 1-}$) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µpg; Hib antigen in an amount of 13 µpg; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 40 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 8 DU and type 3

(Saukett strain ~~or Sabin strain~~) in an amount of 32 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v); propylparaben in an amount of 0.1 mg (w/v).

~~52.~~19. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µ~~p~~g; Hib antigen in an amount of 8 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of 14 IOU; HBsAg in an amount of 15 µ~~p~~g; Hib antigen in an amount of 10 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of ; 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µ~~p~~g; Hib antigen in an amount of 13 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v); methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v).

~~53.~~20. The immunogenic composition as claimed in ~~any one of the preceding~~ claim~~s~~ 1, wherein 0.5 ml of the composition comprises either one of the following:

a) D antigen in an amount of 10 Lf; T antigen in an amount of 2 Lf; wP antigen in an amount of 12 IOU; HBsAg in an amount of 8 µ~~p~~g; ~~H~~Hib antigen in an amount of 8 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

b) D antigen in an amount of 20 Lf; T antigen in an amount of 4 Lf; wP antigen in an amount of14 IOU; HBsAg in an amount of 15 µ~~p~~g; Hib antigen in an amount of 10 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, type 2 (MEF-l strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2-Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v); or

c) D antigen in an amount of 25 Lf; T antigen in an amount of 10 Lf; wP antigen in an amount of 16 IOU; HBsAg in an amount of 15 µ~~p~~g; Hib antigen in an amount of 13 µ~~p~~g; IPV antigen, type 1 (Mahoney strain ~~or Sabin strain~~) in an amount of 7.5 DU, type 2 (MEF-1 strain ~~or Sabin strain~~) in an amount of 1.5 DU and type 3 (Saukett strain ~~or Sabin strain~~) in an amount of 6 DU, respectively; total aluminium content (Al^{3+}) not more than 0.55 mg; 2- Phenoxyethanol in an amount of 2.5 mg (v/v);methylparaben in an amount of 0.9 mg (w/v); propylparaben in an amount of 0.1 mg (w/v).

~~54.~~21. A process of manufacturing a fully liquid multi-dose immunogenic composition, wherein 0.5 ml of the composition comprises~~ing~~:

i) a diphtheria toxoid, (D)in an amount of 10 Lf to 25 Lf, adsorbed onto aluminium salt having percentage adsorption of at least 50%;

ii) a tetanus toxoid, (T)in an amount of 2 Lf to 10 Lf, adsorbed onto aluminium salt having percentage adsorption of at least 40%;

iii) an inactivated whole cell pertussis, (wP) containing inactivated Bordetella pertussis strains 134, 509, 25525 and 6229 in a ratio of 1:1:0.25:0.25, in an amount of 12 IOU to 16 IOU~~or acellular pertussis, (aP)~~;

iv) a hepatitis B virus surface antigen, (~~PIBsAg~~HBsAg)in the an amount of 7 µg to 15 µg, adsorbed onto aluminium salt having percentage adsorption of at least 50%;

v) a Haemophilus influenzae type b antigen, (Hib)in an amount of 7 µg to 13 µg;

vi) an inactivated polio virus antigen, (IPV) containing IPV Type 1 in an amount of 1-25 DU, IPV Type 2in an amount of 1-10 DU and IPV Type 3 in an amount of 1-20 DU;~~and~~

vii) total aluminium adjuvant content (Al3+) in the range of 0.1 mg to 0.6 mg; and

~~vii)~~viii) ~~a combination of~~preservative as 2-phenoxyethanolin an amount of 1 - 6 mg (v/v); methylparabenin an amount of 0.1 – 1.5 mg (w/v) and propylparaben in an amount of 0.05 – 0.2 mg (w/v) ~~and at least one paraben ester~~; or
2-phenoxyethanol in an amount of 1 - 6 mg (v/v) and methylparaben in an amount of 0.1 – 1.5 mg (w/v); or
2-phenoxyethanol in an amount of 1 - 6 mg (v/v) and propylparaben in an amount of 0.05 – 0.2 mg (w/v);

the process comprising the steps of:

a) Addition of 80 % of total Normal saline (NaCl) in a blending vessel / container;

b) Addition of Component - 1 comprising Diphtheria Toxoid in a blending vessel/ container;

c) Addition of Component - II comprising Tetanus Toxoid to Component – I of Step-(b) with agitation at room temperature;

d) Addition of Component - III comprising inactivated whole cel~~l~~ lpertussis antigen to mixture obtained in Step-(c) with agitation at room temperature~~or acellular pertussis, (aP)~~;

e) Addition of Component - IV comprising Hepatitis B surface Antigen to mixture obtained in Step-(d) at room temperature;

f) Addition of Component - V comprising Hib Antigen to the mixture obtained in Step-(e) at 6-16 °C;

g) Addition of Component - VI comprising IPV antigen to the mixture obtained in Step-(f) at 6-16 °C;~~wherein IPV type 1 (Mahoney strain or Sabin strain) in an amount of 1 - 50 DU per 0.5 ml; and IPV type 3 (Saukett strain or Sabin strain) in an amount of 1 - 50 DU per 0.5 ml~~;

h) Addition of a preservative combination to the mixture obtained in Step-(g) at 6-16 °C selected from~~selected from~~:

2-Phenoxyethanol in an amount of 1 to 6 mg per 0.5 ml (v/v) and methylparaben in an amount of 0.1 - 1.5 mg per 0.5 ml (w/v); or

2-Phenoxyethanol in an amount of 1 to 6 mg per 0.5 ml(v/v)and propylparaben in an amount of 0.05 - 0.2 mg per 0.5 ml (w/v); or

2-Phenoxyethanol in an amount of 1 to 6 mg per 0.5 ml(v/v), methylparaben in an amount of 0.1 - 1.5 mg per 0.5 ml (w/v) and propylparaben in an amount of 0.05 - 0.2 mg per 0.5 ml (w/v);

i) Adjusting pH of the mixture obtained in Step-(h) to 6.0 to 7.0 with Sodium Hydroxide / Sodium Carbonate; and

j) Adding remaining 20% of total normal saline (NaCl) to make up the volume with agitation.

~~55. The process as claimed in claim 54. wherein the component - VI further comprises of IPV antigen type 2 (MEF-1 strain or Sabin strain) in an amount of 1 - 20 DU per 0.5 ml.~~

~~56.~~22. The process as claimed in claim ~~54~~21, wherein the preparation of the component I comprises the following steps:

a) Transfer of Aluminium phosphate in the container / vessel;
b) Addition of the Diphtheria Toxoid;
c) pH adjustment to 4.5 to 5.5 with Acetic Acid / Sodium Hydroxide;
d) stabilization;
e) pH adjustment to 5.5 to 6.5 with Sodium Hydroxide / Sodium Carbonate; and
f) stabilization with histidine buffer.

~~57.~~23. The process as claimed in claim ~~54~~21, wherein the preparation of the component II comprises the following steps:

a) Transfer of Aluminium phosphate in the container / Vessel;
b) addition of the Tetanus Toxoid;
c) pH adjustment to 4.5 to 5.5 with Acetic Acid / Sodium Hydroxide;
d) stabilization;
e) pH adjustment to 5.5 to 6.5 with Sodium Hydroxide / Sodium Carbonate; and
f) stabilization with histidine buffer.

~~58.~~24. The process as claimed in claim ~~54~~21, wherein the preparation of the component III comprises the following steps:

a) inactivation at 56°C for 10 - 15 minutes in presence of formaldehyde of Bordetella pertussis strain~~s~~ 134;
b) inactivation at 56°C for 10 - 15 minutes in presence of formaldehyde of Bordetella pertussis strain~~s~~ 509;
c) inactivation at 56°C for 10 - 15 minutes in presence of formaldehyde of Bordelella pertussis strain~~s~~ 25525~~ and 6229~~;
d) inactivation at 56°C for 10 - 15 minutes in presence of formaldehyde of Bordetella pertussis strain~~s~~ 6229;
e) subsequently mixing inactivated Bordetella pertussis strains 134, 509, 25525 and6229 in a ratio of 1:1:0.25:0.25; and
f) optionally adsorbed onto aluminium based adjuvant;

wherein the process is devoid of thiomersal and inactivated whole cell pertussis antigen remains non-clumpy and homogeneous thereby leading to reduced reactogenicity and giving better potency for a longer duration.

~~59.~~25. The process as claimed in claim ~~54~~21, wherein the preparation of the component IV comprises the following steps:

a) Transfer of aluminium phosphate in the container / Vessel;
b) addition of the Hepatitis B surface Antigen;
c) pH adjustment to 4.5 to 5.5 with Acetic Acid / Sodium Hydroxide;
d) stabilization;
e) pH adjustment to 5.8 to 6.8 with Sodium Hydroxide / Sodium Carbonate; and
f) stabilization.

~~60.~~26. The process as claimed in claim ~~54~~21, wherein the preparation of Component - V comprises the following steps:

a) Fermentation of Haemophilus influenzae Type b;
b) Inactivation at 37 °C for 2 hours in presence of 0.1% formaldehyde;
c) Purification of Hib polyribosylribitol phosphate (PRP) polysaccharide;
d) Conjugation of purified product of step c to tetanus toxoid (TT) using a Cyanogen Bromide cyanylation conjugation chemistry in presence of adipic acid dihydrazide (ADH) linker;
e) purification of conjugate of step d; and
f) filtration of purified conjugate preferably through 0.22 pm filter;

wherein the percentage free PRP is no more than 5% in the total purified Hib bulk conjugate.

~~61. A fully liquid multi-dose immunogenic composition, wherein 0.5 ml of the composition comprises D antigen in an amount of 10 to 25 Lf; T antigen in an amount of 2 to 10 Lf; wP antigen in an amount of 12 to 16 IOU; HBsAg in an amount of 7 to 15 pg; Hib~~

~~antigen in an amount of 7 to 13 pg; IPV antigen, Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, Type 2 (MEF-l strain or Sabin strain) in an amount of 1 - 10 DU and Type 3 (Saukett strain or Sabin strain) in an amount of 1 - 20 DU, respectively; total aluminium content (Al^{3+}) in an amount of 0.1 to 0.6 mg; 2-Phenoxyethanol in an amount of 1 to 6 mg (v/v);~~

~~wherein the composition is prepared by the following process:~~

~~a) Addition of Normal saline in a blending vessel / container;~~

~~b) Addition of Component - 1 comprising Diphtheria Toxoid;~~

~~c) Addition of Component - II comprising Tetanus Toxoid;~~

~~d) Addition of Component - III comprising inactivated whole cell pertussis antigen or acellular pertussis, (aP);~~

~~e) Addition of Component - IV comprising Hepatitis B surface Antigen;~~

~~f) Addition of Component - V comprising Hib Antigen;~~

~~g) Addition of Component - VI comprising IPV antigen wherein IPV Type 1 (Mahoney strain or Sabin strain) in an amount of 1 -25 DU, Type 2 (MEF-l strain or Sabin strain) in an amount of 1 - 10 DU and Type 3 (Saukett strain or Sabin strain) in an amount of 1 - 20 DU;~~

~~h) Addition of 2-Phenoxyethanol in an amount of 1 to 6 mg per 0.5 ml (v/v)~~

~~i) Adjusting pH to 6.0 to 7.0 with Sodium Hydroxide / Sodium Carbonate; and~~

~~j) Adding normal saline to make up the volume.~~